HGEN Humanigen, Inc. Stock Quote

HGEN [NASD]

Index	-	P/E	-	EPS (ttm)	-3.18	Insider Own	21.12%	Shs Outstand	65.59M	Perf Week	12.78%
Market Cap	149.94M	Forward P/E	5.27	EPS next Y	0.39	Insider Trans	7.32%	Shs Float	56.39M	Perf Month	-11.35%
Income	-192.40M	PEG	-	EPS next Q	-0.31	Inst Own	42.00%	Short Float	11.23%	Perf Quarter	-0.98%
Sales	4.10M	P/S	36.57	EPS this Y	-66.90%	Inst Trans	0.05%	Short Ratio	4.07	Perf Half Y	-70.28%
Book/sh	-0.38	P/B	-	EPS next Y	81.80%	ROA	-224.90%	Target Price	16.43	Perf Year	-89.01%
Cash/sh	0.93	P/C	2.18	EPS next 5Y	12.50%	ROE	-	52W Range	1.67 - 23.53	Perf YTD	-45.43%
Dividend	-	P/FCF	-	EPS past 5Y	21.90%	ROI	-	52W High	-91.37%	Beta	-0.95
Dividend %	-	Quick Ratio	1.00	Sales past 5Y	-	Gross Margin	-	52W Low	21.56%	ATR	0.21
Employees	11	Current Ratio	1.00	Sales Q/Q	100.00%	Oper. Margin	-	RSI (14)	47.21	Volatility	9.71% 10.91%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	73.90%	Profit Margin	-	Rel Volume	0.73	Prev Close	2.03
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.56M	Price	2.03
Recom	2.30	SMA20	3.94%	SMA50	-21.54%	SMA200	-64.13%	Volume	0	Change	0.00%

Sep-10-21

Downgrade

Jefferies

Buy → Hold

Sep-09-21

Reiterated

H.C. Wainwright

Buy

$36 → $28

Sep-09-21

Downgrade

JP Morgan

Neutral → Underweight

Sep-09-21

Downgrade

Credit Suisse

Outperform → Neutral

Jun-11-21

Initiated

Credit Suisse

Outperform

$28

May-07-21

Initiated

Oppenheimer

Outperform

$30

Feb-23-21

Initiated

JP Morgan

Neutral

$21

Dec-23-20

Initiated

National Securities

Buy

$35

Dec-22-20

Initiated

Jefferies

Buy

$27

Oct-21-20

Initiated

Cantor Fitzgerald

Overweight

$25

Oct-14-20

Initiated

H.C. Wainwright

Buy

$31

Oct-01-20

Initiated

ROTH Capital

Buy

$25

May-11-22 08:43PM	Humanigen: A Transformative Year Awaits, Says Analyst TipRanks -11.33%
May-09-22 06:15AM	Investors in Humanigen (NASDAQ:HGEN) from a year ago are still down 89%, even after 14% gain this past week Simply Wall St. -12.56%
May-05-22 04:00PM	Humanigen Reports First Quarter 2022 Financial Results Business Wire -7.54%
May-04-22 07:00AM	Humanigen Announces Participation and Presentation at Multiple Conferences in May Business Wire
Apr-19-22 06:30AM	Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS Business Wire
Apr-07-22 01:35PM	Humanigen, Inc.'s (NASDAQ:HGEN) Path To Profitability Simply Wall St. -5.84%
Mar-17-22 03:47PM	Insiders Buy These 2 Stocks at Discounted Prices Analysts Say They Have Over 200% Upside Potential TipRanks +7.20%
Feb-28-22 01:05PM	Humanigen Reports Year-End 2021 Financial Results Business Wire
Feb-25-22 05:55AM	Humanigen to Present and Participate at Multiple Investor Events in March Business Wire
Feb-11-22 05:55AM	Humanigen to Present at BIO CEO & Investor Conference Business Wire
Feb-09-22 11:55PM	Humanigen Launches Managed Access Program for Lenzilumab Business Wire
Feb-08-22 11:55PM	Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France Business Wire -6.07%
Feb-06-22 08:26AM	What Kind Of Shareholders Own Humanigen, Inc. (NASDAQ:HGEN)? Simply Wall St.
Jan-18-22 05:55AM	Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab Business Wire -5.61%
Jan-10-22 05:55AM	Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T Business Wire
Jan-06-22 03:11PM	Why 2022 Holds Hope for Humanigen Stock, According to This Analyst TipRanks -5.61%
Jan-05-22 06:05AM	Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved Business Wire -11.53%
Jan-04-22 05:55AM	Humanigen to Present at Investor Conferences January 7 and 13, 2022 Business Wire
Jan-03-22 05:55AM	Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels Business Wire
Dec-15-21 08:59AM	Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022 Business Wire
Dec-01-21 06:45PM	Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update Business Wire -8.09%
06:30PM	The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results Business Wire
Nov-22-21 06:30AM	Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021 Business Wire
Nov-16-21 07:47AM	Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference Business Wire
Nov-12-21 04:00PM	Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update Business Wire
Nov-11-21 06:30AM	Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease Business Wire
Nov-07-21 08:34AM	Investors in Humanigen (NASDAQ:HGEN) have made a impressive return of 172% over the past three years Simply Wall St.
Nov-05-21 10:34AM	Humanigen Announces Release of Abstracts at ASH Business Wire -8.90%
07:04AM	Humanigen: All You Need to Know Right Now TipRanks
Nov-02-21 08:30AM	Humanigen Announces Participation and Presentation at Multiple Conferences in November Business Wire +5.54%
Oct-26-21 05:31PM	European Commission Selects Humanigens Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 Business Wire +5.61%
06:30AM	First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML) Business Wire
Oct-22-21 07:00AM	Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM21 Business Wire
Oct-20-21 07:00AM	Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors Business Wire
Oct-19-21 07:00AM	Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab Business Wire
Oct-11-21 12:53PM	Humanigens Budget Impact Model Demonstrates Lenzilumabs Potential Positive Economic Value in Hospitalized COVID-19 Patients Business Wire
12:23PM	Humanigen Stock to $28? This Analyst Thinks So TipRanks
Oct-08-21 02:00AM	Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe Business Wire
Oct-04-21 11:00PM	Humanigen Announces Participation and Presentation at Multiple Conferences in October Business Wire
Oct-01-21 09:00AM	Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UKs MHRA Business Wire
Sep-29-21 08:00AM	Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021 Business Wire
Sep-28-21 08:28AM	Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab Business Wire
Sep-27-21 10:58AM	Humanigen: Lenzilumab Could Reach the UK Market in 1Q22, Says Analyst TipRanks
Sep-21-21 05:02PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN Newsfile
Sep-20-21 12:38AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN PR Newswire -8.20%
Sep-14-21 12:56PM	Humanigen Announces Participation and Presentation at Multiple Conferences in September Business Wire
Sep-10-21 01:10PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Humanigen, Inc. (HGEN) Investigation ACCESSWIRE -13.68%
11:52AM	Has Humanigen Stock Hit Bottom? Oppenheimer Looks for the Silver Lining TipRanks
Sep-09-21 09:43PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN PR Newswire -47.25%
02:15PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Humanigen, Inc. (HGEN) Investigation ACCESSWIRE
12:16AM	FDA has declined Humanigens Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients Business Wire
Aug-25-21 09:14AM	Humanigen: Lenz Could Become a $1.45 Billion Drug, if Approved, Says Analyst TipRanks
Aug-12-21 04:00PM	Humanigen Reports Second Quarter 2021 Financial Results Business Wire
Aug-09-21 03:19AM	Is Humanigen (NASDAQ:HGEN) Using Too Much Debt? Simply Wall St. +7.55%
Aug-04-21 06:00AM	Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients Business Wire
Aug-02-21 02:02PM	Humanigen: Shares Could More Than Double From Here, Says 5-Star Analyst TipRanks
Jul-30-21 11:06AM	NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19 Business Wire
Jul-26-21 08:00AM	Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development GlobeNewswire
Jul-22-21 09:59AM	Humanigens Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab Business Wire
Jul-13-21 06:51PM	Humanigen: Covid-19 Drug Has Good Odds for EUA Approval, Says Analyst TipRanks
Jul-12-21 08:40AM	Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock? Zacks
Jul-09-21 06:30AM	UKs MHRA accepts Humanigens submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review Business Wire
Jun-28-21 11:46AM	Humanigen Inc. Added to Russell 3000(R) Index Newsfile
Jun-25-21 02:27AM	What Is The Ownership Structure Like For Humanigen, Inc. (NASDAQ:HGEN)? Simply Wall St.
Jun-14-21 06:30AM	Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA) Business Wire
Jun-07-21 08:00AM	Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations Business Wire +11.30%
Jun-03-21 08:00AM	Humanigen to Present at the 2021 LD Micro Invitational XI Business Wire -5.79%
May-28-21 09:00AM	Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19 Business Wire -11.04%
May-26-21 08:30AM	GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021 Business Wire +8.35%
May-19-21 07:00AM	Humanigen to Present at Jefferies Healthcare Conference Business Wire
May-17-21 08:00AM	Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab Business Wire +6.03%
May-13-21 04:01PM	Humanigen Reports First Quarter 2021 Financial Results Business Wire
10:15AM	Are Options Traders Betting on a Big Move in Humanigen (HGEN) Stock? Zacks
May-11-21 04:19AM	Calculating The Intrinsic Value Of Humanigen, Inc. (NASDAQ:HGEN) Simply Wall St.
May-05-21 11:53AM	Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab in Hospitalized COVID-19 Patients Business Wire +5.43%
Apr-21-21 07:00AM	Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer Business Wire +10.71%
Apr-19-21 07:00AM	Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study Business Wire -5.70%
Apr-09-21 08:19AM	Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme Business Wire
08:02AM	Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock? Zacks
Apr-06-21 02:02PM	Humanigen Announces Closing of Public Offering of Common Stock Business Wire
Mar-30-21 08:08PM	Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock Business Wire
Mar-29-21 04:11PM	Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock Business Wire +54.47%
07:00AM	Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19 Business Wire
06:00AM	Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19 Business Wire
Mar-19-21 07:00AM	Humanigen Sets Date for Virtual Annual Shareholders Meeting Business Wire -5.64%
Mar-12-21 01:30AM	Humanigen, Inc. (NASDAQ:HGEN) On The Verge Of Breaking Even Simply Wall St.
Mar-10-21 04:01PM	Humanigen Announces $80 Million Loan Facility from Hercules Capital Business Wire
04:00PM	Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update Business Wire
Mar-08-21 08:34AM	Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't? Zacks +5.85%
Mar-05-21 04:32PM	Humanigen to Present at Roth Conference Business Wire
Mar-02-21 07:00AM	Humanigen Expands its anti-GM-CSF Patent Portfolio Business Wire
Feb-25-21 07:30AM	Humanigen to Present at Multiple Investor Conferences in March Business Wire -6.54%
Feb-11-21 07:30AM	Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences Business Wire
Feb-08-21 07:00AM	Humanigen Elects Dr. Dale Chappell to Board of Directors Business Wire
Feb-04-21 02:37PM	IBD 50 Stocks To Watch: Emergent BioSolutions, A Biotech Stock With Solid Biodefense Cred Investor's Business Daily +6.79%
Feb-03-21 07:00AM	Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing Business Wire
Jan-29-21 07:00AM	Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19 Business Wire
Jan-27-21 07:00AM	Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study PR Newswire
07:00AM	Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study Business Wire
Jan-25-21 01:21PM	Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug MarketWatch

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which has completed pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chappell Dale	Chief Scientific Officer	Mar 11	Buy	3.00	1,000,000	3,000,000	7,944,985	Mar 15 06:23 PM
Kilcoyne Adrian	Chief Medical Officer	Mar 09	Buy	2.78	5,000	13,900	12,000	Mar 14 04:37 PM
Kilcoyne Adrian	Chief Medical Officer	Mar 08	Buy	2.53	7,000	17,710	7,000	Mar 14 04:37 PM
Durrant Cameron	Chief Executive Officer	Mar 02	Buy	2.34	40,000	93,600	70,000	Mar 04 06:06 AM
Jordan Edward P.	Chief Commercial Officer	Mar 02	Buy	2.32	12,500	29,000	12,500	Mar 04 06:05 AM
Chappell Dale	Chief Scientific Officer	Aug 12	Sale	17.16	57,551	987,564	873,693	Aug 13 09:28 PM
Chappell Dale	Chief Scientific Officer	Aug 11	Sale	17.07	109,647	1,872,146	878,009	Aug 13 09:28 PM
Chappell Dale	Chief Scientific Officer	Jul 29	Sale	17.03	29,394	500,703	884,029	Jul 30 09:01 PM
Chappell Dale	Chief Scientific Officer	Jul 28	Sale	17.04	9,692	165,162	886,233	Jul 30 09:01 PM
Chappell Dale	Chief Scientific Officer	Jul 23	Sale	17.04	5,584	95,155	886,960	Jul 23 08:32 PM
Chappell Dale	Chief Scientific Officer	Jul 22	Sale	17.04	178,005	3,032,796	887,379	Jul 23 08:32 PM
Chappell Dale	Chief Scientific Officer	Jul 21	Sale	17.14	132,764	2,275,124	900,729	Jul 23 08:32 PM
Chappell Dale	Chief Scientific Officer	Jul 14	Sale	17.06	15,177	258,847	910,686	Jul 16 08:28 PM
Chappell Dale	Chief Scientific Officer	Jul 09	Sale	17.37	296,036	5,142,767	911,824	Jul 09 09:01 PM
Chappell Dale	Chief Scientific Officer	Jul 08	Sale	17.17	48,010	824,111	934,027	Jul 09 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 25	Sale	17.80	1,000,000	17,803,500	972,361	Jun 25 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 24	Sale	18.37	139,529	2,563,831	1,047,361	Jun 25 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 23	Sale	18.28	133,126	2,434,182	1,057,826	Jun 25 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 18	Sale	18.50	402,480	7,445,558	1,067,811	Jun 21 08:57 PM
Chappell Dale	Chief Scientific Officer	Jun 17	Sale	19.17	181,423	3,478,441	1,097,997	Jun 21 08:57 PM
Chappell Dale	Chief Scientific Officer	Jun 16	Sale	19.41	158,486	3,076,187	1,111,604	Jun 21 08:57 PM
Durrant Cameron	Chief Executive Officer	Jun 14	Sale	20.64	81,441	1,680,934	30,000	Jun 16 09:40 PM
Jordan Edward P.	Chief Commercial Officer	Jun 08	Option Exercise	9.65	14,700	141,855	14,700	Jun 09 05:10 PM
Jordan Edward P.	Chief Commercial Officer	Jun 08	Sale	20.08	14,700	295,176	0	Jun 09 05:10 PM
Chappell Dale	Chief Scientific Officer	Jun 07	Sale	19.08	80,636	1,538,793	1,124,334	Jun 09 04:45 PM
Chappell Dale	Chief Scientific Officer	Jun 04	Sale	18.46	127,084	2,346,415	1,137,066	Jun 04 06:07 PM
Chappell Dale	Chief Scientific Officer	Jun 03	Sale	18.37	191,154	3,511,308	1,157,132	Jun 04 06:07 PM
Chappell Dale	Chief Scientific Officer	Jun 02	Sale	19.01	76,126	1,447,269	1,187,314	Jun 04 06:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience